MLTX Deadline: MLTX Investors Have Opportunity to Lead MoonLake Immunotherapeutics Securities Fraud Lawsuit

Core Points - Rosen Law Firm is reminding purchasers of MoonLake Immunotherapeutics common stock about the December 15, 2025 lead plaintiff deadline for a class action lawsuit [1][3] - Investors who purchased shares during the specified Class Period may be entitled to compensation without any out-of-pocket fees through a contingency fee arrangement [2] Company Details - The complaint alleges that during the Class Period, defendants made false and misleading statements regarding the efficacy of SLK compared to traditional monoclonal antibodies, specifically concerning the molecular targets and clinical benefits [5] - The lawsuit claims that when the true details were revealed, investors suffered damages due to the misleading information provided by the defendants [5] Legal Process - To join the class action, investors can submit a form or contact the law firm directly for more information [3][6] - It is noted that no class has been certified yet, and investors are not represented by counsel unless they retain one [7]